21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Alternativas terapéuticas de osteonecrosis maxilar asociada a medicamentos (ONMAM) reportes de dos casos clínicos y revisión de la literatura Translated title: Therapeutic alternatives for drug-associated maxillary osteonecrosis (MRONJ): reports of two clinical cases and review of the literature. reportes de dos casos clínicos y revisión de la literatura Translated title: Alternativas terapêuticas de osteonecrose maxilar associada a medicamentos (ONMAM): relato de dois casos clínicos e revisão da literatura reportes de dos casos clínicos y revisión de la literatura

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Resumen

          Introducción

          La Osteonecrosis Maxilar asociada a Medicamentos (ONMAM) constituye uno de los efectos adversos más relevantes en el tratamiento con drogas antirresortivas como bifosfonatos y denosumab. Patologías oncológicas como mieloma múltiple, cáncer de mama, próstata, y alteraciones óseas-metabólicas como la osteoporosis lideran las indicaciones para estas terapias antirresortivas. El tratamiento es complejo debido a que muchas veces, la enfermedad es refractaria a la terapéutica aplicada. Se describen tratamientos farmacológicos, conservadores y quirúrgicos.

          Objetivo

          El objetivo de este trabajo es reportar dos casos clínicos de ONMAM tratados con dos protocolos terapéuticos diferentes y el análisis de la literatura disponible en la actualidad sobre estos aspectos en base a la clasificación clínica definida por la American Association of Oral and Maxillofacial Surgeons (AAOMS).

          Conclusión

          Los pacientes que desarrollan cuadros clínicos bucales de gran morbilidad como lo es ONMAM, pueden ver condicionada su calidad de vida y sufrir un agravamiento de su patología de base. El tratamiento de ONMAM está condicionado al estadio de la enfermedad, el éxito del mismo depende del manejo interdisciplinario y de un estricto seguimiento clínico médico y odontológico, así como también un riguroso monitoreo para evitar o detectar precozmente futuras recurrencias.

          Abstract

          Introduction

          Drug-associated Maxillary Osteonecrosis is one of the most relevant adverse effects in treatment with antiresorptive drugs such as bisphosphonates and denosumab. Oncological conditions such as multiple myeloma, breast cancer, prostate, and bone-metabolic disorders such as osteoporosis lead the indications for these antiresorptive therapies. Treatment is complex because the disease is often refractory. Pharmacological, conservative and surgical treatments are described.

          Objective

          The aim of this study is to report two clinical cases of MRONJ treated with two different therapeutic protocols and the analysis of the available literature on these aspects based on the clinical classification defined by the American Association of Oral and Maxillofacial Surgeons (AAOMS).

          Conclusion

          Patients who develop clinical signs of great morbidity associated with MRONJ, may see their quality of life conditioned and suffer a worsening of their underlying pathology. MRONJ treatment is conditioned by the stage of the disease, its success depends on interdisciplinary management and strict medical and dental clinical follow-up, as well as rigorous monitoring to prevent or detect future recurrences early.

          Resumo

          Introdução

          A Osteonecrose Maxilar Associada a Medicamentos (ONMAM) é um dos efeitos adversos mais relevantes no tratamento com drogas antirreabsortivas como bifosfonatos e denosumab. Patologias oncológicas como mieloma múltiplo, câncer de mama, próstata e distúrbios ósseo-metabólicos como osteoporose lideram as indicações para essas terapias antirreabsortivas. O tratamento é complexo porque a doença é muitas vezes refratária à terapia aplicada. Tratamentos farmacológicos, conservadores e cirúrgicos são descritos.

          Objetivo

          O objetivo deste trabalho é relatar dois casos clínicos de OMNAM tratados com dois protocolos terapêuticos diferentes e a análise da literatura atualmente disponível sobre esses aspectos com base na classificação clínica definida pela American Association of Oral and Maxillofacial Surgeons (AAOMS).

          Conclusão

          Pacientes que desenvolvem quadros clínicos bucais de grande morbidade, como o ONMAM, podem ter sua qualidade de vida condicionada e sofrer um agravamento de sua patologia de base. O tratamento do ONMAM é condicionado pelo estágio da doença, seu sucesso depende de manejo interdisciplinar e acompanhamento clínico médico e odontológico rigoroso, além de acompanhamento rigoroso para prevenir ou detectar precocemente futuras recidivas.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

          Strategies for management of patients with, or at risk for, medication-related osteonecrosis of the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) position papers in 2007 and 2009. The position papers were developed by a special committee appointed by the board and composed of clinicians with extensive experience in caring for these patients and basic science researchers. The knowledge base and experience in addressing MRONJ has expanded, necessitating modifications and refinements to the previous position paper. This special committee met in September 2013 to appraise the current literature and revise the guidelines as indicated to reflect current knowledge in this field. This update contains revisions to diagnosis, staging, and management strategies and highlights current research status. The AAOMS considers it vitally important that this information be disseminated to other relevant health care professionals and organizations.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

              Bisphosphonates inhibit bone resorption and thus bone renewal by suppressing the recruitment and activity of osteoclasts thus shortening their life span. Recently three bisphosphonates, Pamidronate (Aredia; Novartis Pharmaceuticals, East Haven, NJ), Zoledronate (Zometa; Novartis Pharmaceuticals), and Alendronate (Fosamax; Merck Co, West Point, VA) have been linked to painful refractory bone exposures in the jaws. One hundred-nineteen total cases of bisphosphonate-related bone exposure were reviewed. Thirty-two of 119 patients (26%) received Aredia, 48 (40.3%) received Zometa, 36 (30.2%) received Aredia later changed to Zometa, and 3 (2.5%) received Fosamax. The mean induction time for clinical bone exposure and symptoms was 14.3 months for those who received Aredia, 12.1 months for those who received both, 9.4 months for those who received Zometa, and 3 years for those who received Fosamax. Sixty-two (52.1%) were treated for multiple myeloma, 50 (42%) for metastatic breast cancer, 4 (3.4%) for metastatic prostate cancer and 3 (2.5%) for osteoporosis. Presenting findings in addition to exposed bone were 37 (31.1%) asymptomatic, 82 (68.9%) with pain, 28 (23.5%) mobile teeth, and 21 (17.6%) with nonhealing fistulas. Eighty-one (68.1%) bone exposures occurred in the mandible alone, 33 (27.7%) in the maxilla, and 5 (4.2%) occurred in both jaws. Medical comorbidities included the malignancy itself 97.5%, previous and/or maintenance chemotherapy 97.5%, Dexamethasone 59.7%. Dental comorbidities included the presence of periodontitis 84%, dental caries 28.6%, abscessed teeth 13.4% root canal treatments 10.9%, and the presence of mandibular tori 9.2%. The precipitating event that produced the bone exposures were spontaneous 25.2%, tooth removals 37.8%, advanced periodontitis 28.6%, periodontal surgery 11.2%, dental implants 3.4% and root canal surgery 0.8%. Complete prevention of this complication in not currently possible. However, pre-therapy dental care reduces this incidence, and non-surgical dental procedures can prevent new cases. For those who present with painful exposed bone, effective control to a pain free state without resolution of the exposed bone is 90.1% effective using a regimen of antibiotics along with 0.12% chlorohexidine antiseptic mouth.
                Bookmark

                Author and article information

                Journal
                Rev Fac Cien Med Univ Nac Cordoba
                Rev Fac Cien Med Univ Nac Cordoba
                Revista de la Facultad de Ciencias Médicas
                Universidad Nacional de Córdoba (Argentina postmaster@ucbscm.edu.ar, postmaster@bfcmcb.sld.ar, cielo@fcmcb.sld.ar, bfcmcb@biomed.uncor.ar )
                0014-6722
                1853-0605
                21 December 2022
                21 December 2022
                : 79
                : 4
                : 379-382
                Affiliations
                [1] Cátedra Medicina Bucal, Escuela de Odontología, Facultad de Ciencias de la Salud, Universidad Católica de Córdoba Córdoba Argentina
                [2 ] Cátedra de Estomatología “A”, Facultad de Odontología, Universidad Nacional de Córdoba Córdoba Argentina
                [3 ] Cátedra Medicina Bucal, Escuela de Odontología, Facultad de Ciencias de la Salud, Universidad Católica de Córdoba Córdoba Argentina
                Author notes
                Author information
                https://orcid.org/0000-0002-4450-0678
                https://orcid.org/0000-0002-5201-1444
                https://orcid.org/0000-0001-5955-1139
                https://orcid.org/0000-0002-5833-5546
                Article
                37.289
                10.31053/1853.0605.v79.n4.37289
                9987302
                36542580
                ee98de1e-af1e-49e5-a0af-46306d9d87c8
                Copyright @

                Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.

                History
                : 05 April 2022
                : 10 May 2022
                Page count
                Figures: 2, Tables: 0, Equations: 0, References: 18, Pages: 4
                Categories
                Casos Clínicos

                osteonecrosis de los maxilares asociada a bifosfonatos,agente antirresortivo,fibrina rica en plaquetas,bisphosphonate induced osteonecrosis of the jaws,bone density conservation agents,platelet-rich fibrin,osteonecrose da arcada osseodentária associada a difosfonatos,conservadores da densidade óssea,fibrina rica em plaquetas

                Comments

                Comment on this article